Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRX 5183

Next Previous
X
Search
Drug Profile

IRX 5183

Alternative Names: AGN 195183; IRX5183; NRX 195183; VTP-195183

Latest Information Update: 07 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer Io Therapeutics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Antipsoriatics
  • Mechanism of Action Immunostimulants; Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Discontinued Psoriasis; Stem cell mobilisation

Most Recent Events

  • 26 Dec 2022 IRX 5183 is still in phase I trials for Acute myeloid leukaemia (Second-line therapy or greater), Chronic myelomonocytic leukaemia (Second-line therapy or greater), Myelodysplastic syndromes (Second-line therapy or greater) in the USA (PO) (Io Therapeutics pipeline, December 2022)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 28 Feb 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top